RP
NVO icon

Ravenswood Partners’s Novo Nordisk NVO Stock Holding History

Ravenswood Partners’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-41,825
Closed -$2.13M – 37
2025
Q4 		$2.13M Buy
41,825
+1,221
+3% +$62.4K 0.71% 31
2025
Q3 		$2.25M Buy
+40,604
New +$2.38M 0.71% 33

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Ravenswood Partners's NVO Position: Q1 2026 in Review

Ravenswood Partners sold out of Novo Nordisk (NVO) in Q1 2026, closing a stake of 41,825 shares — an estimated $2.13M sold.

Ravenswood Partners first reported a position in NVO in Q3 2025 and held it in 2 quarters. The position peaked at $2.25M in Q3 2025. 1,279 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Ravenswood Partners reported no remaining Novo Nordisk position as of Q1 2026 after selling out during the quarter.
  • Ravenswood Partners sold 41,825 Novo Nordisk shares in Q1 2026, an estimated $2.13M.
  • Ravenswood Partners first reported a position in Novo Nordisk in Q3 2025 and held it in 2 quarters.
  • Ravenswood Partners's Novo Nordisk position peaked at $2.25M in Q3 2025.
  • 1,279 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Ravenswood Partners's 13F filing for Q1 2026, filed 12 May 2026.